Abstract

Brain atrophy as measured from structural MR images, is one of the primary imaging biomarkers used to track neurodegenerative disease progression. In diseases such as frontotemporal dementia or Alzheimer's disease, atrophy can be observed in key brain structures years before any clinical symptoms are present. Atrophy is most commonly captured as volume change of key structures and the shape changes of these structures are typically not analysed despite being potentially more sensitive than summary volume statistics over the entire structure.In this paper we propose a spatiotemporal analysis pipeline based on Large Diffeomorphic Deformation Metric Mapping (LDDMM) to detect shape changes from volumetric MRI scans. We applied our framework to a cohort of individuals with genetic variants of frontotemporal dementia and healthy controls from the Genetic FTD Initiative (GENFI) study. Our method, take full advantage of the LDDMM framework, and relies on the creation of a population specific average spatiotemporal trajectory of a relevant brain structure of interest, the thalamus in our case. The residuals from each patient data to the average spatiotemporal trajectory are then clustered and studied to assess when presymptomatic mutation carriers differ from healthy control subjects.We found statistical differences in shape in the anterior region of the thalamus at least five years before the mutation carrier subjects develop any clinical symptoms. This region of the thalamus has been shown to be predominantly connected to the frontal lobe, consistent with the pattern of cortical atrophy seen in the disease.

Highlights

  • Neurodegenerative diseases such as frontotemporal dementia (FTD) present progressive symptoms of behavioural and cognitive dysfunction

  • In this paper we propose a spatiotemporal analysis pipeline based on Large Diffeomorphic Deformation Metric Mapping (LDDMM) to detect shape changes from volumetric magnetic resonance imaging (MRI) scans

  • We applied our framework to a cohort of individuals with genetic variants of frontotemporal dementia and healthy controls from the Genetic FTD Initiative (GENFI) study

Read more

Summary

Introduction

Neurodegenerative diseases such as frontotemporal dementia (FTD) present progressive symptoms of behavioural and cognitive dysfunction. These changes follow many years of a clinically silent phase in the disease, where abnormal proteins slowly accumulates within the brain, leading to neurodegenerative processes that result in loss of function. One common strategy is to investigate people who are at-risk for rare autosomal dominant forms of dementia. Half of these individuals are carriers of the mutation, allowing for comparisons between carriers and non-carriers at various stages within the disease process. As this asymmetry is likely to start early in the disease process, it must be taken into account when looking to detect early changes with any sensitivity

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call